Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gedatolisib in t-AML/MDS and Relapsed/Refractory AML
NCT02438761Phase 2Terminated
- Sponsor
- Institut Curie
- Start
- Aug 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gedatolisib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Institut Curie. Started Aug 2015; status: terminated.
02
Drugs
gedatolisib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02438761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02438761.